US 11,304,742

Application 16/590,804 · Granted Apr 19, 2022

Selective lung tissue ablation

Estimated expiration

December 24, 2026

33 days remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jul 28, 2006
+ 20 years
Jul 28, 2026
PTA +230d
Mar 15, 2027
TD cap (US 10,470,811)
Dec 24, 2026
Final
Dec 24, 2026

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
October 2, 2019
Earliest effective filing
July 28, 2006
Issue date
April 19, 2022
PTA
+230 days
Base expiry (before PTA)
July 28, 2026

July 28, 2006 + 20 years = July 28, 2026 + 230 PTA days = March 15, 2027

  • Continuation of application 15/332,902, filed Oct 24, 2016, issued as US 10,470,811
  • Continuation of application 14/033,163, filed Sep 20, 2013, issued as US 9,486,266
  • Continuation of application 12/606,007, filed Oct 26, 2009, issued as US 8,568,403
  • Continuation of application 11/460,860, filed Jul 28, 2006, issued as US 7,628,789
  • Continuation of application 11/460,860, filed Jul 28, 2006, issued as US 7,628,789
  • Continuation of application 12/606,007, filed Oct 26, 2009, issued as US 8,568,403
  • Continuation of application 11/460,860, filed Jul 28, 2006, issued as US 7,628,789
  • Continuation of application 14/033,163, filed Sep 20, 2013, issued as US 9,486,266
  • Continuation of application 12/606,007, filed Oct 26, 2009, issued as US 8,568,403
  • Continuation of application 11/460,860, filed Jul 28, 2006, issued as US 7,628,789
  • PRO60/709,376 — Provisional — not used for base term
  • PRO60/709,376 — Provisional — not used for base term
  • PRO60/709,376 — Provisional — not used for base term
  • PRO60/709,376 — Provisional — not used for base term
  • PRO60/709,376 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to December 24, 2026 (earliest expiring referenced patent: US 10,470,811)

  • US 10,470,811· Application 15/332,902Capping patent

    Selective lung tissue ablation

    Filing date
    Oct 24, 2016
    Earliest effective filing
    Jul 28, 2006
    Issue date
    Nov 12, 2019
    PTA
    +149 days
    Calculated expiration
    Dec 24, 2026

    Continuation of 14/033,163, filed Sep 20, 2013, issued as US 9,486,266

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Jul 28, 2006 + 20y + 149d PTA = Dec 24, 2026

  • US 9,486,266· Application 14/033,163

    Selective lung tissue ablation

    Filing date
    Sep 20, 2013
    Earliest effective filing
    Jul 28, 2006
    Issue date
    Nov 8, 2016
    PTA
    +257 days
    Calculated expiration
    Apr 11, 2027

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Jul 28, 2006 + 20y + 257d PTA = Apr 11, 2027

  • US 8,568,403· Application 12/606,007

    Selective lung tissue ablation

    Filing date
    Oct 26, 2009
    Earliest effective filing
    Jul 28, 2006
    Issue date
    Oct 29, 2013
    PTA
    +1038 days
    Calculated expiration
    May 31, 2029

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Jul 28, 2006 + 20y + 1038d PTA = May 31, 2029

  • US 7,628,789· Application 11/460,860

    Selective lung tissue ablation

    Filing date
    Jul 28, 2006
    Earliest effective filing
    Jul 28, 2006
    Issue date
    Dec 8, 2009
    PTA
    +412 days
    Calculated expiration
    Sep 13, 2027

    Jul 28, 2006 + 20y + 412d PTA = Sep 13, 2027

  • US 11,304,742· Application 16/590,804(from application 16/590,804)

    Selective lung tissue ablation

    Filing date
    Oct 2, 2019
    Earliest effective filing
    Jul 28, 2006
    Issue date
    Apr 19, 2022
    PTA
    +230 days
    Calculated expiration
    Mar 15, 2027

    Continuation of 15/332,902, filed Oct 24, 2016, issued as US 10,470,811

    Continuation of 14/033,163, filed Sep 20, 2013, issued as US 9,486,266

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Continuation of 14/033,163, filed Sep 20, 2013, issued as US 9,486,266

    Continuation of 12/606,007, filed Oct 26, 2009, issued as US 8,568,403

    Continuation of 11/460,860, filed Jul 28, 2006, issued as US 7,628,789

    Jul 28, 2006 + 20y + 230d PTA = Mar 15, 2027

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 16/590,804 · US 11,304,742

PatentReply compiles the prosecution history behind US 11,304,742: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US11304742

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.